Sunday, March 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Infectious Diseases

Valley Fever: NIH Funds Coccidioidomycosis Collaborative Research Centers

by Global Biodefense Staff
February 6, 2022
Valley Fever: NIH Funds Coccidioidomycosis Collaborative Research Centers

Each year, thousands of people in the United States experience severe cases of Valley Fever, which can lead to long-term respiratory symptoms. In very rare cases, the infection can spread outside of the lungs and cause meningitis, skin lesions, and even death. Currently, there are no vaccines for Valley Fever, and treatment for those with or at risk for developing severe disease usually involves three to six months of antifungal medications.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has announced three awards to establish a network of Coccidioidomycosis Collaborative Research Centers to conduct research on coccidioidomycosis, also known as Valley Fever. These multi-disciplinary research teams will collaborate to investigate potential diagnostics, therapeutics, and vaccines for this fungal disease.

The awards total more than $4.5 million in the first year, and are designed to support research that fills significant knowledge gaps about Valley Fever. For instance, researchers might seek to determine what factors in the host and in the pathogen contribute to the range in severity and outcomes of Valley Fever. Since few researchers currently study Valley Fever, the awards are intended to encourage scientists to focus more collaborative efforts on this disease by pooling their resources and expertise. By emphasizing collaboration and interdisciplinary research, these awards will support work that bridges both basic research and clinical research to facilitate new ways to prevent, diagnose, and treat Valley Fever.

Awards have been made to the following institutions:

University of California, San Francisco
Project Title: Molecules and Pathways at the Coccidioides Host-Pathogen Interface
Grant: 1 U19 AI166798-01

University of California, Los Angeles
Project Title: Host Immunogenetics and Fungal Virulence Mechanisms in Coccidioidomycosis
Grant: 1 U19 AI166059-01

University of Texas, San Antonio
Project Title: Development of Therapeutics and Vaccines Against Coccidioidomycosis
Grant: 1 U19 AI166761-01

Valley Fever, caused by the fungus Coccidioides, is endemic in parts of the southwestern United States as well as in Mexico and Central and South America. Because the fungal spores live in soil, Valley Fever is of particular concern for people who work with soil or spend time in dusty conditions. Infection with Coccidioides is often asymptomatic, but some people suffer from flu-like symptoms, including fatigue, cough and shortness of breath, fever, and rashes.

READ ALSO:

  • Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity Open Forum Infectious Diseases Jan 2022
  • Decoding Transcription Regulatory Mechanisms Associated with Coccidioides immitis Phase Transition Using Total RNA mSystems Jan 2022
  • Health and Safety Effects of Airborne Soil Dust in the Americas and Beyond Review of Geophysics Nov 2021
Tags: AwardsEditor PickValley Fever

Related Posts

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Officials Declare End to Ebola Outbreak in Uganda
Infectious Diseases

Officials Declare End to Ebola Outbreak in Uganda

January 11, 2023
Why Upper Respiratory Infectious are More Common in Colder Temperatures
Infectious Diseases

Why Upper Respiratory Infectious are More Common in Colder Temperatures

December 7, 2022
runners on a track
Infectious Diseases

Feeling Winded After Your Workout? Long COVID May Reduce Exercise Capacity

October 23, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC